TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (“Sosei”)(TOKYO:4565) confirms that Novartis Pharma K.K. launched once-daily Ultibro ® Inhalation Capsules (“Ultibro ® ”; glycopyrronium / indacaterol), ...

Marks first approval for glycopyrronium bromide in COPD, with approval alsoexpected in the EU in 2012 Approval triggers $2.5m milestone payment to Sosei Seebri ® Inhalation Capsules 50 mcg approved as ...

Shares of Cambridge-based Vectura rose after it confirmed the Japanese government has approved its Seebri inhalation capsules used in inhaler devices. The treatment, which will be available to ...

Novartis has taken a leap forward in rolling out its new chronic obstructive pulmonary disease (COPD) franchise with approvals for long-acting muscarinic antagonist (LAMA) Seebri in the EU and Japan.

Novartis ($NVS) has submitted the once-daily inhaled combination drug QVA149 for approval in Europe for the treatment of COPD in adults. This triggered a $5 million ...

·; Seebri®Inhalation Capsules 50 mcg approved as maintenance COPD treatment will be available to patients and physicians in Japan by year-end ·; Marks first approval for glycopyrronium bromide in COPD ...

The European Commission has approved Novartis’ Seebri Breezhaler to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). This follows last week’s approval of Seebri ...

Ask your doctor if you are not sure. Do not swallow Utibron or Seebri capsules. Only use Utibron or Seebri capsules with the Neohaler inhaler. Never place a capsule in the mouthpiece of the Neohaler ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has entered into an exclusive license agreement with Novartis for the U.S. commercialization ...

Seebri ® Breezhaler ® 44 mcg delivered dose approved for maintenance treatment of COPD will be available to patients and physicians in some EU markets by year-end In GLOW trials, Seebri ® Breezhaler ® ...